Robert Schwab is an instructor in hematology–oncology at Perelman School of Medicine, University of Pennsylvania, where he combines clinical training with cutting-edge immunotherapy research. He earned his medical degree from the same institution and completed residency in internal medicine followed by a fellowship in hematology-oncology. Over the past several years, Schwab has helped extend the reach of cell-based therapies beyond cancer — most recently co-leading development of a novel CAR-T regulatory cell (CAR Treg) targeting oxidized LDL (OxLDL) to reduce artery-plaque formation in preclinical models of atherosclerosis. His work represents an effort to translate powerful immune-modulating technologies into treatments for common diseases like heart disease, potentially opening new therapeutic avenues beyond oncology.